Hepatitis C

Digestive Disease Week® (DDW)

May 6, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.

Earn CME and MOC Credit in the March Journals

March 27, 2017

Three new quizzes are now available covering celiac disease, hepatitis C and defecatory disorders.

New HCV Treatments Work Well for Severe Liver Disease

March 21, 2017

New therapies are safe and effective in patients with decompensated cirrhosis. Find out more in the AGA-MedPage Today Reading Room.

Unrestricted DAA Access Halved Dutch HCV Incidence in HIV

March 6, 2017

GI & Hepatology News reports on a new study finding that new hepatitis C infections among HIV-positive men were halved in the Netherlands by unrestricted access to direct-acting antivirals.

HCV Genotype 1 No Longer a Treatment Bugbear

Feb. 17, 2017

While treatment failure is rare, there are therapy nuances. Article discusses in the AGA MedPage Today Reading Room.

Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities

Feb. 1, 2017

We conducted a phase 4, open-label study with limited exclusion criteria to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus genotype 2 infection, and compensated cirrhosis.

Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation

Feb. 1, 2017

We investigated whether patients who maintained SVR12 with DAA agents after liver transplantation had occult HCV infections.
Advertisement

Eradication of HCV in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Jan. 23, 2017

This MedPage Today AGA Reading Room article reviews the effects of a sustained viral response on outcomes of patients with HCV.

Registration Open for 2017 AGA Postgraduate Course

Jan. 11, 2017

Early access to registration is open for AGA members. Secure your spot a week before general registration opens and save $75.

2017 AGA Postgraduate Course Online Sessions

Jan. 4, 2017

Pre-order the on-demand online sessions from the 2017 AGA Postgraduate Course: The Full Scope of GI Advances to learn key treatment advances that you can immediately implement in your practice.

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

Jan. 2, 2017

The combination tablet of elbasvir and grazoprevir, with or without ribavirin, was highly efficacious in inducing an SVR12 in patients with HCV.

Arterial-Portal Fistula After Percutaneous Liver Biopsy in Hepatic Allograft Causing Hemobilia and Pancreatitis

Jan. 2, 2017

A 59-year-old man with HCV infection and HCC presented with acute onset epigastric pain and melena.

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Jan. 2, 2017

We performed a prospective study to investigate the effects of SVR on outcomes of patients with HCV infection and compensated cirrhosis.

Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis

Nov. 22, 2016

This large cohort study showed that therapy is safe and effective in patients with compensated (CP score of A) cirrhosis.

HIV and Hepatitis Management: THE NEW YORK COURSE

Nov. 17, 2016

This advanced CME activity will provide participants with state-of-the-art information and practical guidance from internationally recognized experts on progress in managing HIV, hepatitis B and hepatitis C.

GI Patient Education Materials at Your Fingertips

Oct. 31, 2016

As an AGA member, you have free, quick and easy access to the new AGA Patient INFO Center’s robust library of GI patient education materials.

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

Oct. 28, 2016

We found sofosbuvir-velpatasvir plus GS-9857 to be safe and effective for patients with HCV with or without compensated cirrhosis.

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

Oct. 28, 2016

We found 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to be safe and effective in treatment-naive patients.

Can HCV Treatment Reactivate Herpesvirus Infection?

Oct. 25, 2016

CGH researchers report reactivation of herpesvirus in 10 patients with HCV infection treated with direct-acting antiviral agents. Learn more on the AGA Journals Blog.

Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents

Oct. 25, 2016

We performed a case-series analysis of reactivation of herpesvirus in patients with HCV treated with DAA agents.

Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease

Oct. 25, 2016

We found patients with HCC to be more likely to be placed on liver transplant wait lists than patients with decompensated cirrhosis.

GI Quality Measures for 2017 Released in MACRA Final Rule

Oct. 19, 2016

While 2017 is a transition year for MACRA, GIs need to report quality measures to succeed.

Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen

Sept. 27, 2016

We assessed the presence of hepatitis C virus RNA in liver explants from 39 patients awaiting liver transplantation who were treated with an interferon-free regimen and had undetectable serum HCV RNA at the time of liver transplantation.

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Sept. 27, 2016

In cirrhotic HCV GT1- or GT3-infected patients, ABT-493 plus ABT-530 with or without RBV achieved SVR12 rates of 96%–100% and was well tolerated.